Ovid Therapeutics Inc. (NASDAQ:OVID) to Post Q2 2025 Earnings of $0.18 Per Share, William Blair Forecasts

Ovid Therapeutics Inc. (NASDAQ:OVID) – Equities research analysts at William Blair upped their Q2 2025 earnings per share estimates for Ovid Therapeutics in a report issued on Monday, July 1st. William Blair analyst T. Lugo now anticipates that the company will post earnings of $0.18 per share for the quarter, up from their prior estimate of $0.12. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.81) per share.

Other research analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of Ovid Therapeutics in a research report on Tuesday. Oppenheimer cut Ovid Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 18th. Wedbush began coverage on Ovid Therapeutics in a research report on Friday, April 5th. They issued an “outperform” rating and a $8.00 price objective for the company. Citigroup cut their price objective on Ovid Therapeutics from $3.50 to $1.20 and set a “neutral” rating for the company in a research report on Tuesday, June 18th. Finally, B. Riley decreased their price objective on shares of Ovid Therapeutics from $9.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, June 18th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $4.70.

Ovid Therapeutics Stock Performance

Ovid Therapeutics stock opened at $0.77 on Wednesday. Ovid Therapeutics has a 12 month low of $0.68 and a 12 month high of $4.14. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.47 and a current ratio of 10.47. The business has a 50 day simple moving average of $2.54 and a 200-day simple moving average of $3.04.

Ovid Therapeutics (NASDAQ:OVID) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. Ovid Therapeutics had a negative return on equity of 53.62% and a negative net margin of 10,691.14%. The business had revenue of $0.15 million during the quarter, compared to analysts’ expectations of $0.11 million.

Hedge Funds Weigh In On Ovid Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. raised its stake in Ovid Therapeutics by 17.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 81,173 shares of the company’s stock worth $312,000 after purchasing an additional 11,926 shares during the period. SG Americas Securities LLC boosted its stake in Ovid Therapeutics by 52.7% during the 4th quarter. SG Americas Securities LLC now owns 39,792 shares of the company’s stock valued at $128,000 after acquiring an additional 13,728 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in Ovid Therapeutics during the 4th quarter valued at $253,000. China Universal Asset Management Co. Ltd. bought a new position in Ovid Therapeutics during the 4th quarter valued at $26,000. Finally, FFT Wealth Management LLC bought a new position in shares of Ovid Therapeutics in the 4th quarter worth about $1,274,000. Hedge funds and other institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.